Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Mesothelioma | Research

Asbestos ban policies and mesothelioma mortality in Greece

Authors: Evdoxia Gogou, Chryssi Hatzoglou, Dimitra Siachpazidou, Sotirios G. Zarogiannis, Konstantinos I. Gourgoulianis

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

Malignant mesothelioma is a rare form of cancer that mostly affects the pleura and has a strong link to asbestos exposure. Greece banned the use of asbestos in 2005, however, the public was already aware of this substance in the 1980s. This research aims to present an overview of Greece’s mesothelioma age-standardized mortality rates (ASMR) from 1983 to 2019 by age, gender, and geographic region and to determine whether the actions to ban asbestos impacted these rates.

Methods

Data were retrieved by the Hellenic Statistical Authority (HSA) from death certificates that mentioned mesothelioma as the cause of death from 1983 to 2019 with details on the residence, gender, and age. Statistical analysis was performed using PRISM 6.0 software, a two-way ANOVA test, Trend analysis was conducted using Joinpoint Regression Program 5.0 software. The linear and non-linear model was used to calculate the age-standardized rates of annual percentage change (APC) and its 95% confidential interval (95% CI).

Results

From 1983 to 2019, 850 total mesothelioma deaths were recorded, the majority of whom were males (634). A rate of 74.6% accounts for males and 25.4% for females, and the ratio of Males: Females was 3:1. Males’ ASMR and the whole population’s ASMR reached their highest levels in 2011 (0.93/100000person-years and 0.53/100000person-years, respectively). To look for potential changes between the first two decades of the 21st century, we compared the mean ASMR of each geographic region in Greece between two different 10-year subperiods (2000–2009 and 2010–2019). Except for Epirus, all regions of Greece had elevated regional ASMRs, particularly in those with the highest asbestos deposits. Notably, the ASMR in Epirus decreased from 0.54/100000person-years (2000–2009) to 0.31/100000person-years (2010–2019). After 2011, the ASMR for men and the general population stabilized. This stability is important since mesothelioma in men is associated with occupational asbestos exposure. The intriguing discovery of a lower ASMR in Epirus emphasizes the need to raise awareness of the condition and implement effective public health measures.

Conclusions

In Greece, the annual ASMR for males and the whole population reached its highest level in 2011, which is positive and encouraging and may be a sign that the rate will stabilize during the following years. Moreover, this study showed that the actions made in the 1980s regarding public awareness and surveillance directly impacted the decrease in Epirus rates. Future research, continual awareness, information, and recording are needed to monitor the mesothelioma epidemic. The possible benefit of a mesothelioma registry and the epidemiological surveillance of asbestos-related diseases, particularly mesothelioma mortality, need to be addressed.

Trial registration

Not applicable.
Appendix
Available only for authorised users
Literature
2.
go back to reference Consonni D, Calvi C, Matteis S De, Mirabelli D, Landi MT, Caporaso NE, et al. Peritoneal mesothelioma and asbestos exposure: a population-based case– control study in Lombardy, Italy. Occup. Environ Med. 2019;76:545–53.CrossRefPubMed Consonni D, Calvi C, Matteis S De, Mirabelli D, Landi MT, Caporaso NE, et al. Peritoneal mesothelioma and asbestos exposure: a population-based case– control study in Lombardy, Italy. Occup. Environ Med. 2019;76:545–53.CrossRefPubMed
3.
go back to reference Marinaccio A, Consonni D, Mensi C, Mirabelli D, Migliore E, Magnani C, et al. Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case–control study and epidemiological remarks. Scand J Work Environ Health. 2020;46(6):609–17.CrossRefPubMedPubMedCentral Marinaccio A, Consonni D, Mensi C, Mirabelli D, Migliore E, Magnani C, et al. Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case–control study and epidemiological remarks. Scand J Work Environ Health. 2020;46(6):609–17.CrossRefPubMedPubMedCentral
6.
go back to reference Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792–802.CrossRefPubMed Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792–802.CrossRefPubMed
7.
go back to reference Forman D, Bray F, Brewster DH, Gombe MBalawa C, Kohler B, Pineros M, et al. Cancer incidence in five continents vol. X. IARC Scientific Publications. 2014;No 164. Forman D, Bray F, Brewster DH, Gombe MBalawa C, Kohler B, Pineros M, et al. Cancer incidence in five continents vol. X. IARC Scientific Publications. 2014;No 164.
10.
go back to reference Alpert N, van Gerwen M, and Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–38.CrossRefPubMedPubMedCentral Alpert N, van Gerwen M, and Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–38.CrossRefPubMedPubMedCentral
11.
go back to reference Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet. 2007;369:844–49.CrossRefPubMed Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet. 2007;369:844–49.CrossRefPubMed
13.
go back to reference Zhai Z, Ruan J, Zheng Y, Xiang D, Li N, Hu J, et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Network Open. 2021;4(8):e2120360.CrossRefPubMedPubMedCentral Zhai Z, Ruan J, Zheng Y, Xiang D, Li N, Hu J, et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Network Open. 2021;4(8):e2120360.CrossRefPubMedPubMedCentral
17.
go back to reference Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, and Roggli VL. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018;142(6):753–60.CrossRefPubMed Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, and Roggli VL. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018;142(6):753–60.CrossRefPubMed
19.
go back to reference Smith AH, and Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med. 1996;30:252–66.CrossRefPubMed Smith AH, and Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med. 1996;30:252–66.CrossRefPubMed
23.
go back to reference IARC monographs on the evaluation of carcinogenic risks to humans: arsenic, metals, and dust. 2012;100 C. IARC monographs on the evaluation of carcinogenic risks to humans: arsenic, metals, and dust. 2012;100 C.
24.
go back to reference Amand-Eeckhout L. EU legislation in progress: protection of workers from asbestos at work. Eur Parliam Res Serv Introd. 2023;PE 749.813. Amand-Eeckhout L. EU legislation in progress: protection of workers from asbestos at work. Eur Parliam Res Serv Introd. 2023;PE 749.813.
28.
go back to reference Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski JE, Parkin DM, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes and Control. 2003;14:791–803.CrossRefPubMed Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski JE, Parkin DM, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes and Control. 2003;14:791–803.CrossRefPubMed
29.
go back to reference Van Kooten JP, Belderbos RA, Von Der Thüsen JH, Aarts MJ, Verhoef C, Burgers JA, et al. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. Thorax. 2022;77:1260–67.CrossRefPubMed Van Kooten JP, Belderbos RA, Von Der Thüsen JH, Aarts MJ, Verhoef C, Burgers JA, et al. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. Thorax. 2022;77:1260–67.CrossRefPubMed
33.
go back to reference Burdorf A, Jarvholm B, and Englunt A. Explaining differences in incidence rates of pleural mesothelioma between Sweden and the Netherlands. Int J Cancer. 2005;113:298–301.CrossRefPubMed Burdorf A, Jarvholm B, and Englunt A. Explaining differences in incidence rates of pleural mesothelioma between Sweden and the Netherlands. Int J Cancer. 2005;113:298–301.CrossRefPubMed
35.
go back to reference Gogou E, Kerenidi T, Chamos V, Zintzaras E, and Gourgoulianis KI. Mesothelioma mortality in Greece from 1983 to 2003. Int J Clin Pract. 2009;63(6):944–8.CrossRefPubMed Gogou E, Kerenidi T, Chamos V, Zintzaras E, and Gourgoulianis KI. Mesothelioma mortality in Greece from 1983 to 2003. Int J Clin Pract. 2009;63(6):944–8.CrossRefPubMed
38.
go back to reference Constantopoulos SH, Goudevenos JA, Saratzis N, Langer AM, Selikoff IJ, and Moutsopoulos HM. Metsovo lung: pleural calcification and restrictive lung function in northwestern Greece. Environmental exposure to mineral fiber as etiology. Environ Res. 1985;38(2):319–31.CrossRefPubMed Constantopoulos SH, Goudevenos JA, Saratzis N, Langer AM, Selikoff IJ, and Moutsopoulos HM. Metsovo lung: pleural calcification and restrictive lung function in northwestern Greece. Environmental exposure to mineral fiber as etiology. Environ Res. 1985;38(2):319–31.CrossRefPubMed
39.
go back to reference Bazas T, Oakes D, Gilson JC, Bazas B, and McDonald JC. Pleural calcification in northwest Greece. Environ Res. 1985;38(2):239–47.CrossRefPubMed Bazas T, Oakes D, Gilson JC, Bazas B, and McDonald JC. Pleural calcification in northwest Greece. Environ Res. 1985;38(2):239–47.CrossRefPubMed
41.
go back to reference Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–96.PubMedPubMedCentral Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–96.PubMedPubMedCentral
44.
go back to reference Metintas M, Metintas S, Ak G, Erginel S, Alatas F, Kurt E, et al. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology. 2008;13(1):117–21.CrossRefPubMed Metintas M, Metintas S, Ak G, Erginel S, Alatas F, Kurt E, et al. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology. 2008;13(1):117–21.CrossRefPubMed
45.
go back to reference Gogou E, Kerenidi T, Chamos V, Hatzoglou C, and Gourgoulianis KI. Environmental asbestos exposure alters the male: female ratio in patients with pleural mesothelioma. Respirology. 2008;13(6):931.CrossRefPubMed Gogou E, Kerenidi T, Chamos V, Hatzoglou C, and Gourgoulianis KI. Environmental asbestos exposure alters the male: female ratio in patients with pleural mesothelioma. Respirology. 2008;13(6):931.CrossRefPubMed
46.
go back to reference Baur X, Frank AL, Soskolne CL, Oliver LC, and Magnani C. Malignant mesothelioma: ongoing controversies about its etiology in females. Am J Ind Med. 2021;64:543–50.CrossRefPubMed Baur X, Frank AL, Soskolne CL, Oliver LC, and Magnani C. Malignant mesothelioma: ongoing controversies about its etiology in females. Am J Ind Med. 2021;64:543–50.CrossRefPubMed
48.
go back to reference Mazurek JM, Syamlal G, Wood JM, Hendricks SA, and Weston A. Malignant mesothelioma mortality — United States, 1999–2015. MMWR. 2017;66(8):214–8.PubMedPubMedCentral Mazurek JM, Syamlal G, Wood JM, Hendricks SA, and Weston A. Malignant mesothelioma mortality — United States, 1999–2015. MMWR. 2017;66(8):214–8.PubMedPubMedCentral
50.
go back to reference Newhouse ML, and Berry G. Predictions of mortality from mesothelial tumours in asbestos factory workers. British J Industrial Medicine. 1976;33:147–51. Newhouse ML, and Berry G. Predictions of mortality from mesothelial tumours in asbestos factory workers. British J Industrial Medicine. 1976;33:147–51.
51.
go back to reference Peto J, Seidman H, and Selikoff IJ. Mesothelioma in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer. 1982;45:124–35.CrossRefPubMedPubMedCentral Peto J, Seidman H, and Selikoff IJ. Mesothelioma in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer. 1982;45:124–35.CrossRefPubMedPubMedCentral
53.
go back to reference McDonald JC, Harris JM, and Berry G. Sixty years on: the price of assembling military gas masks in 1940. Occup Env Med. 2006;63:852–55.CrossRef McDonald JC, Harris JM, and Berry G. Sixty years on: the price of assembling military gas masks in 1940. Occup Env Med. 2006;63:852–55.CrossRef
54.
go back to reference Harding AH, and Darnton AJ. Asbestosis and mesothelioma among British Asbestos workers (1971–2005). Am J Ind Med. 2010;53:1070–80.CrossRefPubMed Harding AH, and Darnton AJ. Asbestosis and mesothelioma among British Asbestos workers (1971–2005). Am J Ind Med. 2010;53:1070–80.CrossRefPubMed
56.
go back to reference Segura O, Burdorf A, and Looman C. Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med. 2003;60:50–55.CrossRefPubMedPubMedCentral Segura O, Burdorf A, and Looman C. Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med. 2003;60:50–55.CrossRefPubMedPubMedCentral
57.
go back to reference Peto J, Decarli A, La Vecchia C, Levi F, and Negri E. The European mesothelioma epidemic. British J Cancer. 1999;79(3/4):666–72.CrossRef Peto J, Decarli A, La Vecchia C, Levi F, and Negri E. The European mesothelioma epidemic. British J Cancer. 1999;79(3/4):666–72.CrossRef
62.
go back to reference Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Scarselli A, Ferrante P, et al. The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. Occup Environ Med. 2018;75:254–62.CrossRefPubMed Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Scarselli A, Ferrante P, et al. The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. Occup Environ Med. 2018;75:254–62.CrossRefPubMed
64.
go back to reference Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, et al. Consensus report of the 2015 Weinman international conference on mesothelioma. J Thorac Oncol. 2016;11(8):1246–62. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, et al. Consensus report of the 2015 Weinman international conference on mesothelioma. J Thorac Oncol. 2016;11(8):1246–62.
65.
go back to reference Panou V, and Røe OD. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int J Mol Sci. 2020;21(12):4327.CrossRefPubMedPubMedCentral Panou V, and Røe OD. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int J Mol Sci. 2020;21(12):4327.CrossRefPubMedPubMedCentral
66.
go back to reference Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36(35):3485–94.CrossRefPubMedCentral Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36(35):3485–94.CrossRefPubMedCentral
67.
go back to reference Kato S, Tomson BN, Buys TPH, Elkin SK, Carter JL, and Kurzrock R. Genomic landscape of malignant mesotheliomas. Mol Cancer Ther. 2016;15(10):2498–507.CrossRefPubMed Kato S, Tomson BN, Buys TPH, Elkin SK, Carter JL, and Kurzrock R. Genomic landscape of malignant mesotheliomas. Mol Cancer Ther. 2016;15(10):2498–507.CrossRefPubMed
70.
go back to reference Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81.CrossRefPubMed Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81.CrossRefPubMed
71.
go back to reference Sakellariou K, Malamou-Mitsi V, Haritou A, Koumpaniou C, Stachouli C, Dimoliatis ID, et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? Eur Respir J. 1996;9(6):1206–10.CrossRefPubMed Sakellariou K, Malamou-Mitsi V, Haritou A, Koumpaniou C, Stachouli C, Dimoliatis ID, et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? Eur Respir J. 1996;9(6):1206–10.CrossRefPubMed
Metadata
Title
Asbestos ban policies and mesothelioma mortality in Greece
Authors
Evdoxia Gogou
Chryssi Hatzoglou
Dimitra Siachpazidou
Sotirios G. Zarogiannis
Konstantinos I. Gourgoulianis
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Mesothelioma
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18030-x

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue